Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada Life Sciences Division, TRIUMF, 4004 Wesbrook ...
New preclinical findings demonstrate ATNM-400 overcomes resistance to the EGFR inhibitor osimertinib in EGFR-mutated NSCLC, addressing a major unmet clinical need NEW YORK, Oct. 13, 2025 /PRNewswire/ ...
Oral presentation by Dr Zan highlighted novel Phase 1/2 SANTANA-225 study design of 225Ac-SSO110 in patients with ES-SCLC or MCC 225Ac-SSO110 achieves superior pharmacokinetics with minimal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback